Literature DB >> 18406820

Estrogen receptors and cell proliferation in breast cancer.

D R Ciocca1, M A Fanelli.   

Abstract

Most of the actions of estrogens on the normal and abnormal mammary cells are mediated via estrogen receptors (ERs), including control of cell proliferation; however, there are also alternative pathways of estrogen action not involving ERs. Estrogens control several genes and proteins that induce the cells to enter the cell cycle (protooncogenes, growth factors); estrogens also act on proteins directly involved in the control of the cell cycle (cyclins), and moreover, estrogens stimulate the response of negative cell cycle regulators (p53, BRCA1). The next challenge for researchers is elucidating the integration of the interrelationships of the complex pathways involved in the control of cell proliferation. This brief review focuses on the mechanisms of estrogen action to control cell proliferation and the clinical implications in breast cancer. (Trends Endocrinol Metab 1997;8:313-321). (c) 1997, Elsevier Science Inc.

Entities:  

Year:  1997        PMID: 18406820     DOI: 10.1016/s1043-2760(97)00122-7

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  20 in total

1.  Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer.

Authors:  Yoshikazu Johmura; Ichiro Maeda; Narumi Suzuki; Wenwen Wu; Atsushi Goda; Mariko Morita; Kiyoshi Yamaguchi; Mizuki Yamamoto; Satoi Nagasawa; Yasuyuki Kojima; Koichiro Tsugawa; Natsuko Inoue; Yasuo Miyoshi; Tomo Osako; Futoshi Akiyama; Reo Maruyama; Jun-Ichiro Inoue; Yoichi Furukawa; Tomohiko Ohta; Makoto Nakanishi
Journal:  J Clin Invest       Date:  2018-11-12       Impact factor: 14.808

2.  Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin.

Authors:  Q He; C H Liang; S J Lippard
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

3.  Identification of a hormone-regulated dynamic nuclear actin network associated with estrogen receptor alpha in human breast cancer cell nuclei.

Authors:  Concetta Ambrosino; Roberta Tarallo; Angela Bamundo; Danila Cuomo; Gianluigi Franci; Giovanni Nassa; Ornella Paris; Maria Ravo; Alfonso Giovane; Nicola Zambrano; Tatiana Lepikhova; Olli A Jänne; Marc Baumann; Tuula A Nyman; Luigi Cicatiello; Alessandro Weisz
Journal:  Mol Cell Proteomics       Date:  2010-03-22       Impact factor: 5.911

4.  Estrogen receptor-alpha hinge-region lysines 302 and 303 regulate receptor degradation by the proteasome.

Authors:  Nicholas B Berry; Meiyun Fan; Kenneth P Nephew
Journal:  Mol Endocrinol       Date:  2008-04-03

5.  Systematic mapping of posttranslational modifications in human estrogen receptor-alpha with emphasis on novel phosphorylation sites.

Authors:  Christian Atsriku; David J Britton; Jason M Held; Birgit Schilling; Gary K Scott; Bradford W Gibson; Christopher C Benz; Michael A Baldwin
Journal:  Mol Cell Proteomics       Date:  2008-11-03       Impact factor: 5.911

6.  Expression of ER, Ki-67 and cylinD1 in the pre-cancerous breast of Chinese patients.

Authors:  Cheng-Jun Zhou; Qing-Hui Zhang; Ting-Guo Zhang; Shan-Zhen Sun; Hong Li; Yan Wang; Zhi-Yan Liu
Journal:  Pathol Oncol Res       Date:  2008-10-22       Impact factor: 3.201

7.  Estradiol-mediated tumor neo-vascularization.

Authors:  Shilpi Rajoria; Robert Suriano; Yushan L Wilson; Andrea L George; Jan Geliebter; Stimson P Schantz; Raj K Tiwari
Journal:  Oncol Lett       Date:  2011-03-21       Impact factor: 2.967

Review 8.  Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvement.

Authors:  Molly M Morgan; Brian P Johnson; Megan K Livingston; Linda A Schuler; Elaine T Alarid; Kyung E Sung; David J Beebe
Journal:  Pharmacol Ther       Date:  2016-05-21       Impact factor: 12.310

9.  Estrogen induced metastatic modulators MMP-2 and MMP-9 are targets of 3,3'-diindolylmethane in thyroid cancer.

Authors:  Shilpi Rajoria; Robert Suriano; Andrea George; Arulkumaran Shanmugam; Stimson P Schantz; Jan Geliebter; Raj K Tiwari
Journal:  PLoS One       Date:  2011-01-18       Impact factor: 3.240

10.  Revealing Adverse Outcome Pathways from Public High-Throughput Screening Data to Evaluate New Toxicants by a Knowledge-Based Deep Neural Network Approach.

Authors:  Heather L Ciallella; Daniel P Russo; Lauren M Aleksunes; Fabian A Grimm; Hao Zhu
Journal:  Environ Sci Technol       Date:  2021-07-25       Impact factor: 11.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.